IGF1 and renal cell carcinoma: Prospective studies evaluating the association between directly measured fasting insulin (prediagnostically) and RCC risk are further warranted, and improving our understanding of insulin and IGF1 signaling in RCC development and progression may also offer therapeutic opportunities [36].